The Food and Drug Administration has granted expedited approval to a once-monthly therapeutic designed to directly pay a patient’s landlord, though regulators warn the intervention's long-term safety profile remains under review. Initial clinical trials suggest the direct-deposit protocol significantly reduces self-reported dread, though researchers note the results may be influenced by a limited sample size.
The treatment, administered via a $2,200 electronic transfer on the first of the month, demonstrated a notable reduction in clinical hopelessness among a cohort of 400 moderately depressed renters. However, a paper published Tuesday in JAMA Psychiatry emphasized that the correlation between housing security and the desire to remain alive requires further double-blind investigation to isolate the specific causal pathways.
While self-reported mood improved dramatically within hours of the funds clearing, we must caution that the difference between correlation and causation in financial therapeutics is still poorly understood.
The FDA guidance also highlighted potential risk factors associated with the regimen. During Phase 3 trials, participants receiving the monthly rent disbursement frequently exhibited sudden, uncharacteristic urges to purchase fresh produce, which researchers warn could severely confound the baseline metabolic data.
The National Institutes of Health has reportedly declined to fund trials for a generic, lower-dose version of the protocol, observing that a $600 partial payment failed to achieve any clinical efficacy against a standard residential lease.